Table 2.
Large-scale studies about MMR deficiency in Lung Carcinoma.
| Study | Examined cases | Frequency of MSI-H | Sex | Histopathology | Stage | Smoking history | Other carcinoma | PD-L1 expression | p53 expression |
|---|---|---|---|---|---|---|---|---|---|
| Warth et al. (24) | 480 (ADC) | 4 (0.8%) | Female (1), Male (3) | ADC | All of stage I | All | Esophagus (1), Kidney (1), Pancreas (1) | ND | ND |
| Takamochi et al. (25) | 341 (ADC) | 1 (0.3%) | Male (1) | ADC | ND | All | No history | No | ND |
| Vanderwalde et al. (26) | 1868 (NSCLC) | 12 (0.6%) | ND | ND | ND | ND | ND | ND | ND |
| Yanagawa et al. (our study, 2021) | 1153 (Lung carcinoma) | 2 (0.17%) | Male (2) | SQCC (1) and combined SCLC (1)* | stage I (1), stage II (1) | All | Stomach (1), colon (1) | No (1), High (1) | positive (2) |
MMR, mismatch repair; ADC, adenocarcinoma; NSCLC, non-small cell lung carcinoma; MSI, microsatellite instability; SQCC, squamous cell carcinoma; SCLC, small cell lung carcinoma; ND, not do.